Raphael Pharmaceutical (RAPH) CTO exercises 350,000 warrants into common stock
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Raphael Pharmaceutical Inc. Chief Technology Officer Louria Hayon Igal exercised warrants to acquire 350,000 shares of common stock at an exercise price of $0.01 per share. Following the in-the-money derivative exercise, her direct common stock holdings increased to 1,349,000 shares, with no such warrants remaining outstanding.
Positive
- None.
Negative
- None.
Insider Trade Summary
350,000 shares exercised/converted
Mixed
2 txns
Insider
Louria Hayon Igal
Role
Chief Technology Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| X | Warrants to purchase Common Stock | 350,000 | $0.00 | -- |
| X | Common Stock | 350,000 | $0.01 | $4K |
Holdings After Transaction:
Warrants to purchase Common Stock — 0 shares (Direct);
Common Stock — 1,349,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Warrants Exercised: 350,000 warrants
Exercise Price: $0.01 per share
Shares Acquired: 350,000 shares
+2 more
5 metrics
Warrants Exercised
350,000 warrants
Exercised into common stock
Exercise Price
$0.01 per share
Warrant exercise price
Shares Acquired
350,000 shares
Common stock received on exercise
Shares Held After
1,349,000 shares
Post-transaction common stock holdings
Derivative Exercises Reported
1 transaction
In-the-money derivative exercise
Key Terms
in-the-money derivative exercise, Warrants to purchase Common Stock, exercise price, Common Stock
4 terms
in-the-money derivative exercise financial
"transaction_action: "in-the-money derivative exercise""
Warrants to purchase Common Stock financial
"security_title: "Warrants to purchase Common Stock""
exercise price financial
"the exercise price is reported under column 2 of this table"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did RAPH CTO Louria Hayon Igal report?
Louria Hayon Igal reported exercising warrants to acquire 350,000 shares of Raphael Pharmaceutical common stock. The exercise converted derivative securities into common shares, reflecting an in-the-money derivative exercise rather than an open-market purchase or sale transaction.
At what price were the Raphael Pharmaceutical (RAPH) warrants exercised?
The warrants were exercised at an exercise price of $0.01 per share. This low exercise price indicates an in-the-money derivative exercise, where the conversion terms were favorable relative to the underlying common stock’s value at the time of exercise.
What happened to the Raphael Pharmaceutical (RAPH) warrants after the exercise?
The 350,000 warrants to purchase common stock were fully exercised, leaving zero warrants of that series outstanding for the CTO. The derivative summary in the filing shows no remaining derivative positions following this warrant exercise transaction.
Is the warrant exercise by the RAPH CTO considered a routine transaction?
The filing shows an in-the-money derivative exercise where warrants were converted into common shares at a fixed $0.01 exercise price. Such exercises are typically part of equity compensation arrangements and do not represent discretionary open-market trading activity.